This case series describes adults with aquaporin 4 immunoglobulin G–seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab. This evidence concerns the gene AQP4 and neuromyelitis optica.